Clinical Trial Update: A Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Resectable HER2-Altered Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is studying SHR-A1811 with Adebelimumab as neoadjuvant therapy for resectable HER2-altered non-small cell lung cancer; the study is cur…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Adebelimumab (Adebelimumab)
• SHR-A1811

Snippet

Sponsor: Shanghai Chest Hospital | Conditions: NSCLC | Phase 2 | Status: NOT_YET_RECRUITING